Author information
1Department of Interventional Radiology, University of Miami, Leonard M. Miller School of Medicine Miami, Florida. Electronic address: lindsay.thornton@miami.edu.
2Division of Interventional Radiology, University of California Irvine, Irvine, California.
3Department of Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
4Department of Radiology, National and Kapodistrian University of Athens, Athens, Greece.
5Department of Radiation Oncology, University of Miami, Leonard M Miller School of Medicine, Miami, Florida.
6Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
7Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
8Department of Radiology, Pisa University Hospital and School of Medicine, Pisa, Italy.
9Department of Radiology and Surgical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
10Division of Interventional Radiology, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
11Department of Surgery, Texas Christian University, Burnett School of Medicine, Fort Worth, Texas.
12Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada.
13Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; School of Biomedical Engineering, Faculty of Applied Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Interventional Radiology, University of Miami, Leonard M Miller School of Medicine, Miami, Florida.
Abstract
Hepatocellular carcinoma, historically, has had a poor prognosis with very few systemic options. Furthermore, most patients at diagnosis are not surgical candidates. Therefore, locoregional therapy (LRT) has been widely used, with strong data supporting its use. Over the last 15 years, there has been progress in the available systemic agents. This has led to the updated Barcelona Clinic Liver Cancer (BCLC) algorithm's inclusion of these new systemic agents, with advocacy of earlier usage in those who progress on LRT or have tumor characteristics that make them less likely to benefit from LRT. However, neither the adjunct of LRT nor the specific sequencing of combination therapies is addressed directly. This Research Consensus Panel sought to highlight research priorities pertaining to the combination and optimal sequencing of LRT and systemic therapy, assessing the greatest needs across BCLC stages.